ethyl 5-hydroxy-6-methoxy-2-(morpholinomethyl)benzofuran-3-carboxylate | 1318264-31-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: ethyl 5-hydroxy-6-methoxy-2-(morpholinomethyl)benzofuran-3-carboxylate
• CAS: 1318264-31-1
• 化学式: C₁₇H₂₁NO₆
• 分子量: 335.357
• InChiKey: SHPIMLVSZWMYFS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.16
• 重原子数：
  24.0
• 可旋转键数：
  5.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  81.37
• 氢给体数：
  1.0
• 氢受体数：
  7.0

反应信息

• 作为反应物：
  描述：

  ethyl 5-hydroxy-6-methoxy-2-(morpholinomethyl)benzofuran-3-carboxylate 在 potassium fluoride 、 三甲基铵三氧化硫共聚物 、 caesium carbonate 、 溶剂黄146 、 三乙胺 作用下， 以 乙酸乙酯 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 20.67h， 生成 Sodium;[3-ethoxycarbonyl-2-[[3-ethoxycarbonyl-6-methoxy-2-(morpholin-4-ylmethyl)-1-benzofuran-5-yl]oxymethyl]-6-methoxy-1-benzofuran-5-yl] sulfate
  参考文献：
  名称：

  Rational Design of Potent, Small, Synthetic Allosteric Inhibitors of Thrombin

  摘要：

  Thrombin is a key enzyme targeted by the majority of current anticoagulants that are direct inhibitors. Allosteric inhibition of thrombin may. offer a major advantage of finely tuned regulation. We present here sulfated benzofurans as the first examples of potent, small allosteric inhibitors of thrombin. A sulfated benzofuran library of 15 sulfated monomers and 13 sulfated dimers with different charged, polar, and hydrophobic substituents was studied in this work. Synthesis of the sulfated benzofurans was achieved through a multiple step, highly branched strategy, which culminated with microwave-assisted chemical sulfation. Of the 28 potential inhibitors, 11 exhibited reasonable inhibition of human a.-thrombin at pH 7.4. Structure-activity relationship analysis indicated that sulfation at the 5-position of the benzofuran scaffold was essential for targeting thrombin. A tert-butyl 5-sulfated benzofuran derivative was found to be the most potent thrombin inhibitor with an IC50 of 7.3 mu M under physiologically relevant conditions. Michaelis-Menten studies showed an allosteric inhibition phenomenon. Plasma clotting assays indicate that the sulfated benzofurans prolong both the activated partial thromboplastin time and prothrombin time. Overall, this work puts forward sulfated benzofurans as the first small, synthetic molecules as powerful lead compounds for the design of a new class of allosteric inhibitors of thrombin.

  DOI：

  10.1021/jm2005767
• 作为产物：
  描述：

  ethyl 5,6-dihydroxy-2-methylbenzofuran-3-carboxylate 在 咪唑 、 potassium fluoride 、 N-溴代丁二酰亚胺(NBS) 、 caesium carbonate 、 溶剂黄146 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 45.0h， 生成 ethyl 5-hydroxy-6-methoxy-2-(morpholinomethyl)benzofuran-3-carboxylate
  参考文献：
  名称：

  Rational Design of Potent, Small, Synthetic Allosteric Inhibitors of Thrombin

  摘要：

  Thrombin is a key enzyme targeted by the majority of current anticoagulants that are direct inhibitors. Allosteric inhibition of thrombin may. offer a major advantage of finely tuned regulation. We present here sulfated benzofurans as the first examples of potent, small allosteric inhibitors of thrombin. A sulfated benzofuran library of 15 sulfated monomers and 13 sulfated dimers with different charged, polar, and hydrophobic substituents was studied in this work. Synthesis of the sulfated benzofurans was achieved through a multiple step, highly branched strategy, which culminated with microwave-assisted chemical sulfation. Of the 28 potential inhibitors, 11 exhibited reasonable inhibition of human a.-thrombin at pH 7.4. Structure-activity relationship analysis indicated that sulfation at the 5-position of the benzofuran scaffold was essential for targeting thrombin. A tert-butyl 5-sulfated benzofuran derivative was found to be the most potent thrombin inhibitor with an IC50 of 7.3 mu M under physiologically relevant conditions. Michaelis-Menten studies showed an allosteric inhibition phenomenon. Plasma clotting assays indicate that the sulfated benzofurans prolong both the activated partial thromboplastin time and prothrombin time. Overall, this work puts forward sulfated benzofurans as the first small, synthetic molecules as powerful lead compounds for the design of a new class of allosteric inhibitors of thrombin.

  DOI：

  10.1021/jm2005767